BD Introduces Next-Generation TIPS Innovation to Expand Portal Hypertension Treatment in EU
FRANKLIN LAKES, April 9 — Becton, Dickinson and Company (BD) has announced the CE marking of its Liverty™ TIPS Stent Graft, marking a significant advancement in the treatment of portal hypertension across the European Union.
The next-generation device is designed to expand treatment options for patients suffering from cirrhosis and related complications, including life-threatening conditions such as internal bleeding and fluid accumulation.
Portal hypertension, a common consequence of advanced liver disease, remains a major global health challenge, with millions affected worldwide.
The transjugular intrahepatic portosystemic shunt (TIPS) procedure is widely used to reduce portal pressure and improve blood flow, helping to manage symptoms associated with the condition.
The Liverty™ TIPS Stent Graft introduces enhanced flexibility in treatment through its adjustable inner diameter, ranging from 6 to 10 millimetres, allowing physicians to tailor the procedure to individual patient needs.
It also offers a broader range of stent lengths, supported by a flexible nitinol frame and dual-layer ePTFE encapsulation, designed to improve durability and performance.
The device is delivered using a triaxial system that enables precise placement and greater procedural control, enhancing ease of use for clinicians.
BD’s worldwide president of peripheral intervention Rima Alameddine highlighted the importance of accessible and adaptable treatment options for patients with complex liver conditions.
She noted that the new device allows physicians to personalise therapy more effectively, potentially improving long-term patient outcomes.
BD also announced that data from the ARCH clinical trial will be presented for the first time at the Society of Interventional Radiology Annual Scientific Meeting in April.
The study is a global, prospective, multi-centre trial evaluating the safety and effectiveness of the Liverty™ TIPS Stent Graft in treating complications of portal hypertension.
Global principal investigator Ziv Haskal said the device represents a meaningful advancement in clinical practice, enabling more precise matching of treatment to patient physiology.
He added that the trial provides some of the first prospective data on the use of small-diameter TIPS in managing a wide range of portal hypertension complications.
In the United States, the device remains investigational and is currently limited to research use only.
Overall, the innovation reflects ongoing efforts to advance interventional therapies for liver disease, focusing on improving patient outcomes through more adaptable and personalised medical technologies.
-wilayah.com.my
